000			01742 a2200457 4500
005			20250511152523.0
264		0	_c19760802
008			197608s 0 0 eng d
022			_a0026-0495
024	7		_a10.1016/0026-0495(76)90067-6 _2doi
040			_aNLM _beng _cNLM
100	1		_aMoses, A M
245	0	0	_aPathophysiologic and pharmacologic alterations in the release and action of ADH. _h[electronic resource]
260			_bMetabolism: clinical and experimental _cJun 1976
300			_a697-721 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAnalgesics _xtherapeutic use
650	0	4	_aAnimals
650	0	4	_aAntidepressive Agents, Tricyclic _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aBrain _xsurgery
650	0	4	_aBrain Neoplasms _xphysiopathology
650	0	4	_aCarbamazepine _xtherapeutic use
650	0	4	_aCraniocerebral Trauma _xphysiopathology
650	0	4	_aDemeclocycline _xadverse effects
650	0	4	_aDiabetes Insipidus _xdiagnosis
650	0	4	_aDiuresis _xdrug effects
650	0	4	_aDiuretics _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aLithium _xadverse effects
650	0	4	_aOsmolar Concentration
650	0	4	_aPituitary Gland, Posterior _xmetabolism
650	0	4	_aSodium Chloride
650	0	4	_aSulfonamides
650	0	4	_aSulfonylurea Compounds _xtherapeutic use
650	0	4	_aVasopressins _xanalysis
700	1		_aMiller, M
700	1		_aStreeten, D H
773	0		_tMetabolism: clinical and experimental _gvol. 25 _gno. 6 _gp. 697-721
856	4	0	_uhttps://doi.org/10.1016/0026-0495(76)90067-6 _zAvailable from publisher's website
999			_c826568 _d826568